These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 33051619)

  • 21. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma.
    Hahn AW; Lebenthal J; Genovese G; Sircar K; Tannir NM; Msaouel P
    Cancer Treat Res Commun; 2022; 33():100640. PubMed ID: 36174377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition.
    Boström AK; Möller C; Nilsson E; Elfving P; Axelson H; Johansson ME
    Hum Pathol; 2012 May; 43(5):708-19. PubMed ID: 21992819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
    de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
    Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
    Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
    Merrill MM; Wood CG; Tannir NM; Slack RS; Babaian KN; Jonasch E; Pagliaro LC; Compton Z; Tamboli P; Sircar K; Pisters LL; Matin SF; Karam JA
    Urol Oncol; 2015 Apr; 33(4):166.e21-9. PubMed ID: 25700975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
    Shuch B; Said J; La Rochelle JC; Zhou Y; Li G; Klatte T; Kabbinaavar FF; Pantuck AJ; Belldegrun AS
    J Urol; 2009 Nov; 182(5):2164-71. PubMed ID: 19758641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncological outcomes after partial vs radical nephrectomy in renal cell carcinomas of ≤7 cm with presumed renal sinus fat invasion on preoperative imaging.
    Koo KC; Kim JC; Cho KS; Choi YD; Hong SJ; Yang SC; Ham WS
    BJU Int; 2016 Jan; 117(1):87-93. PubMed ID: 25099267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
    McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
    J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
    Jiang W; Wang D; Liu X; Zheng W; Wen L; Shi H; Zhang H; Zhou A; Li C; Ma J; Zheng S; Shou J
    Urol Oncol; 2021 Jan; 39(1):78.e9-78.e16. PubMed ID: 32988712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD1/PD-L1 therapy in metastatic renal cell carcinoma.
    Bruchbacher A; Lemberger U; Hassler MR; Fajkovic H; Schmidinger M
    Curr Opin Urol; 2020 Jul; 30(4):534-541. PubMed ID: 32453005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
    Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
    J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation.
    Zhao Y; Chen H; Xie Y; Zhang C; Hou Y; Jin M
    APMIS; 2020 May; 128(5):378-386. PubMed ID: 32048364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases.
    Whaley RD; Cheng L
    Am J Surg Pathol; 2022 Sep; 46(9):1171-1179. PubMed ID: 35687360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarcomatoid Chromophobe Renal Cell Carcinoma: A Case Report and Review of the Literature.
    Bian L; Duan J; Wang X; Yang Y; Zhang X; Xiao S
    Am J Case Rep; 2019 Aug; 20():1225-1230. PubMed ID: 31423007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.